187 Clinical sub-phenotypes of Staphylococcus aureus bacteraemia 8 References 1. Wilson R, Hamburger M. Fifteen years’ experience with staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am J Med. 1957;22(3):437-457. 2. Verway M, Brown KA, Marchand-Austin A, et al. Prevalence and Mortality Associated with Bloodstream Organisms: a Population-Wide Retrospective Cohort Study. J Clin Microbiol. 2022;60(4):e0242921. 3. Souli M, Ruffin F, Choi S-H, et al. Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study. Clinical Infectious Diseases. 2019;69(11):1868-1877. 4. Choi SH, Dagher M, Ruffin F, et al. Risk Factors for Recurrent Staphylococcus aureus Bacteremia. Clin Infect Dis. 2021;72(11):1891-1899. 5. Bai AD, Lo CKL, Komorowski AS, et al. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2022;28(8):1076-1084. 6. Westgeest AC, Ruffin F, Kair JL, et al. The association of female sex with management and mortality in patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2023;29(9):1182-1187. 7. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221-2248. 8. Grillo S, Pujol M, Miró JM, et al. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillinsusceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med. 2023;29(10):2518-2525. 9. Dolby HW, Clifford SA, Laurenson IF, Fowler VG, Russell CD. Heterogeneity in Staphylococcus aureus Bacteraemia Clinical Trials Complicates Interpretation of Findings. J Infect Dis. 2022;226(4):723728. 10. Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10121):668-678. 11. Russell CD, Baillie JK. Treatable traits and therapeutic targets: Goals for systems biology in infectious disease. Curr Opin Syst Biol. 2017;2:140-146. 12. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. The Lancet Respiratory Medicine. 2014;2(8):611-620. 13. Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol. 2007;7(1):43-50. 14. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal. 2016;47(2):410-419. 15. Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. European Respiratory Journal. 2016;47(4):1113-1122. 16. Wildi K, Livingstone S, Palmieri C, LiBassi G, Suen J, Fraser J. The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine? J Intensive Care. 2021;9(1):14. 17. Russell CD, Berry K, Cooper G, et al. Distinct clinical endpoints of Staphylococcus aureus bacteraemia complicate assessment of outcome. Clin Infect Dis. 2024. 18. Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791-797. 19. Vermunt JK, Magidson J. Latent class analysis. The sage encyclopedia of social sciences research methods. 2004;2:549--553. 20. Sinha P, Calfee CS, Delucchi KL. Practitioner’s Guide to Latent Class Analysis: Methodological Considerations and Common Pitfalls. Crit Care Med. 2021;49(1):e63-e79. 21. Weller BE, Bowen NK, Faubert SJ. Latent Class Analysis: A Guide to Best Practice. Journal of Black Psychology. 2020;46(4):287-311. 22. Vermunt JK. Latent Class Modeling with Covariates: Two Improved Three-Step Approaches. Political Analysis. 2010;18(4):450-469. 23. Vermunt JK, Magidson J. LG-syntax user’s guide: Manual for latent gold syntax module version
RkJQdWJsaXNoZXIy MTk4NDMw